InsiderDB

Lobbying disclosures · Lobbying report

DHR: third_quarter 2026 lobbying report

Issues pertaining to the regulation of cell and gene therapy products. Issues pertaining to the biomedical research enterprise. H.R. 8646, FY 2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations, Issues related to cell and gene therapy products at FDA.

Follow DHR
Became public
Oct 14, 2026, 4:29 PM EDT
Event / period date
Not stated
Collected
Nov 11, 2026, 2:08 AM EST

Why this is connected

Legal-name match: DANAHER CORPORATION is DANAHER CORP /DE/ (https://www.sec.gov/Archives/edgar/data/313616/), differing only in punctuation, "the" or suffix spelling (Corp/Corporation).

Reported lobbying amounts

Income: $36,000.00

These are different reporting measures. They are not added together or treated as spending on one particular bill.

Source evidence

Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/bb98967e-35c2-43f6-9be9-7f30c0638313/","filing_uuid":"bb98967e-35c2-43f6-9be9-7f30c0638313","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/bb98967e-35c2-43f6-9be9-7f30c0638313/print/","filing_document_content_type":"text/html","income":"36000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"R. Reed Skaggs, Chief Strategy and Business Officer","dt_posted":"2026-10-14T16:29:15-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"250 Massachusetts Ave. NW","registrant_address_2":"Suite 550","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":22781,"url":"https://lda.gov/api/v1/registrants/22781/","house_registrant_id":30442,"name":"LEWIS-BURKE ASSOCIATES, LLC","description":"Lobbying and Consulting Firm","address_1":"440 1st Street NW","address_2":"Suite 700","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"REED SKAGGS","contact_telephone":"+1 202-289-7475","dt_updated":"2026-07-13T12:18:35.067037-04:00"},"client":{"id":73166,"url":"https://lda.gov/api/v1/clients/73166/","client_id":73166,"name":"DANAHER CORPORATION","general_description":"For-profit Company - Biomedical Products","client_government_entity":null,"client_self_select":false,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2026-05-08"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues pertaining to the regulation of cell and gene therapy products. Issues pertaining to the biomedical research enterprise.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152329,"prefix":"ms","prefix_display":"MS.","first_name":"ANJALI","nickname":null,"middle_name":"HELENA","last_name":"TADAVARTHY","suffix":null,"suffix_display":null},"covered_position":"Paid Intern - Washington DC Office of Senator Tina Smith","new":false},{"lobbyist":{"id":152328,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"ANTHONY","last_name":"PETERSON","suffix":null,"suffix_display":null},"covered_position":"Legislative Director, Sen. Leg. Assistant, Leg. Assistant, Leg. Correspondent/Digital Media Specialist, Staff Assistant, Intern, Congressman Peter J. Visclosky","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"H.R. 8646, FY 2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations, Issues related to cell and gene therapy products at FDA.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152329,"prefix":"ms","prefix_display":"MS.","first_name":"ANJALI","nickname":null,"middle_name":"HELENA","last_name":"TADAVARTHY","suffix":null,"suffix_display":null},"covered_position":"Paid Intern - Washington DC Office of Senator Tina Smith","new":false},{"lobbyist":{"id":152328,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"ANTHONY","last_name":"PETERSON","suffix":null,"suffix_display":null},"covered_position":"Legislative Director, Sen. Leg. Assistant, Leg. Assistant, Leg. Correspondent/Digital Media Specialist, Staff Assistant, Intern, Congressman Peter J. Visclosky","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}

Congressional trading in DHR

These disclosures provide context. Their presence does not establish a link between a trader and the event.

Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.